{"symbol":"ABBV","fiscalQuarter":"Q3-2025","reportDate":"2025-10-31","reportTime":"BMO","status":"reported","company":{"name":"AbbVie Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/ABBV/earnings/Q3-2025","postBrief":{"headline":"AbbVie Beats on EPS, Stock Down 4.45%","keyNumbers":[{"metric":"EPS","actual":"$1.86","expected":"N/A","surprise":"+4.91%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted the continued strength in their core products.","They acknowledged challenges in the market but remain focused on long-term growth."],"summary":"Overall, management expressed a cautious optimism about the company's performance. They emphasized their commitment to navigating market challenges."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"AbbVie's earnings report showed a positive surprise in EPS, indicating better-than-expected profitability. However, the stock fell by 4.45%, likely due to investor concerns about revenue performance and market challenges. The lack of guidance may have also contributed to the negative stock reaction, as investors often look for future direction from management.","metaDescription":"AbbVie Inc (ABBV) Q3 2025 earnings: EPS beat by 4.91%. Stock down 4.45%. Full breakdown."}}